---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-24-195950"
form_type: "8-K"
ticker: "CPRX"
cik: "0001369568"
company_name: "CATALYST PHARMACEUTICALS, INC."
filed_at: "2024-08-07T23:59:59+00:00"
generated_at: "2026-05-31T11:39:32.114059+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Catalyst Q2 revenue $122.7M (+23% YoY); GAAP EPS $0.33, non-GAAP $0.56; guides upper end of $455-475M

## Summary
- Total Q2 2024 revenue $122.7M, up 23.3% YoY; FIRDAPSE $77.4M (+19.2%), FYCOMPA $36.5M (+5.7%), AGAMREE $8.7M (new launch).
- GAAP net income $40.8M ($0.33 diluted); non-GAAP net income $69.6M ($0.56 diluted), up 15.3% YoY.
- Cash and equivalents $375.7M at June 30, 2024, up from $137.6M at Dec 31, 2023 (+173%).
- Reaffirms 2024 total revenue guidance of $455-$475M; expects results in upper half of range.
- Announced license agreement for AGAMREE in Canada to expand rare orphan portfolio.

## SEC filing metadata
- accession: 0001193125-24-195950
- form_type: 8-K
- ticker: CPRX
- cik: 0001369568
- company_name: CATALYST PHARMACEUTICALS, INC.
- filed_at: 2024-08-07T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1369568/000119312524195950/0001193125-24-195950-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1369568/000119312524195950/d873312d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-24-195950
- JSON: https://secwatch.observer/filing/0001193125-24-195950.json
- Plain text: https://secwatch.observer/filing/0001193125-24-195950.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.